SCHEMBL13049683

SCHEMBL13049683

OCc1c(-c2ccccc2O)oc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.46
▸ AKR1C2 P52895 1/20 0.46
▸ AKR1C1 Q04828 1/20 0.46
▸ NMUR2 Q9GZQ4 2/20 0.42
▸ MEN1 O00255 6/20 0.40
▸ CYP3A4 P08684 6/20 0.40
▸ KMT2A Q03164 6/20 0.40
▸ HSD17B10 Q99714 5/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ TP53 P04637 4/20 0.40
▸ HPGD P15428 4/20 0.40
▸ ALOX15 P16050 4/20 0.40
▸ CYP2C9 P11712 3/20 0.40
▸ CYP2C19 P33261 3/20 0.40
▸ MAOA P21397 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ ALOX12 P18054 2/20 0.40
▸ RECQL P46063 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2962849 0.77 KMT2A (0.53) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL13049761 0.76 ALDH1A1 (0.52) MEN1KMT2AMAPTTDP1ALDH1A1
SCHEMBL34467629 0.76 NMUR2 (0.51) AKR1C3AKR1C2AKR1C1NMUR2MEN1
SCHEMBL31675811 0.75 NMUR2 (0.71) AKR1C3AKR1C2AKR1C1NMUR2MEN1
SCHEMBL290080 0.75 NMUR2 (0.71) AKR1C3AKR1C2AKR1C1NMUR2MEN1
SCHEMBL27478441 0.74 NQO1 (0.46) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL2428081 0.74 NMUR2 (0.47) AKR1C3AKR1C2AKR1C1NMUR2MEN1
SCHEMBL5795210 0.74 NMUR2 (0.47) AKR1C3AKR1C2AKR1C1NMUR2MEN1
SCHEMBL13049706 0.73 PTPN1 (0.45) MEN1CYP3A4KMT2AHSD17B10KDM4E
SCHEMBL13049678 0.73 KDM4E (0.36) NMUR2MEN1KMT2AHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
US-7837981-B2 Methods for imaging soluble A-beta GENERAL ELECTRIC COMPANY (US) 2010-11-23 — — US disclosed
EP-1631561-B1 COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING OF SOLUBLE BETA-AMYLOID GEN ELECTRIC (US) 2010-08-18 — — EP disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-7727511-B2 Agents for imaging soluble a-beta GENERAL ELECTRIC COMPANY (US) 2010-06-01 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-08-16 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA GENERAL ELECTRIC COMPANY (US) 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070140960-A1 METHODS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 AKR1C3 3266/4885AKR1C2 3390/4885AKR1C1 3276/4885
US-20070189967-A1 AGENTS FOR IMAGING SOLUBLE A-BETA APBA1, APP, FABP7 AKR1C3 3343/4885AKR1C2 3457/4885AKR1C1 3339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback